Cas:139507-52-1 1-phenylmethoxycarbonyl-3-propan-2-ylpiperidine-3-carboxylic acid manufacturer & supplier

Chemical Name:1-phenylmethoxycarbonyl-3-propan-2-ylpiperidine-3-carboxylic acid

CAS.NO:139507-52-1

Synonyms:ethyl 2-(methoxy(methyl)amino)-2-oxoacetate;1-Cbz-3-isopropylpiperidine-3-carboxylic Acid;ethyl 1-(N-methoxy-N-methyl-amino)-1-oxo-acetate;monoethoxyoxalic acid-N-methoxy-N-methylamide;Ethyl [methoxy(methyl)amino]oxoacetate

Molecular Formula:C₁₇H₂₃NO₄

Molecular Weight:305.36900

HS Code:2922509090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:66.84000

Exact Mass:305.16300

LogP:3.08390

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethyl 2-(methoxy(methyl)amino)-2-oxoacetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl [methoxy(methyl)amino]oxoacetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 2-(methoxy(methyl)amino)-2-oxoacetate Use and application,ethyl 1-(N-methoxy-N-methyl-amino)-1-oxo-acetate technical grade,usp/ep/jp grade.

Related News: Under the high pressure of environmental protection, if Chinese API companies want to achieve sustainable operation, they must recognize the current situation, increase environmental investment, and carry out industrial upgrades, focusing on new product development, process improvement, CMO business and new technology research. And other businesses to carry out work to improve safety, environmental protection, quality, cost and other capabilities, so as to seize structural opportunities. 1-phenylmethoxycarbonyl-3-propan-2-ylpiperidine-3-carboxylic acid manufacturer Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. 1-phenylmethoxycarbonyl-3-propan-2-ylpiperidine-3-carboxylic acid supplier The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. 1-phenylmethoxycarbonyl-3-propan-2-ylpiperidine-3-carboxylic acid vendor On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration. 1-phenylmethoxycarbonyl-3-propan-2-ylpiperidine-3-carboxylic acid factory Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion.